Totbiopharm Shanghai R&D Center, 781 Cailun Road, Shanghai, 201203, China.
Curr Cancer Drug Targets. 2018;18(2):171-176. doi: 10.2174/1568009618666171129221503.
The oncolytic viruses now hold a promise of new therapeutic strategy for cancer. Its concept has inspired a wave of commercial research and development activities for the products of this category in China since 1998. The first commercialized oncolytic virus product in the world, Oncorine (H101), developed by Shanghai Sunway Biotech Co., Ltd since 1999, was approved by Chinese SFDA in November, 2005 for nasopharyngeal carcinoma in combination with chemotherapy after the phase III clinical trial, and finally acquired GMP certificate in August, 2006. This review introduces how Oncorine was successfully developed in China, and how the Chinese market responded after it was launched into the market in 2006.
溶瘤病毒为癌症治疗提供了新的策略，这一概念激发了自 1998 年以来中国针对这一类产品的商业研究与开发热潮。1999 年，上海三维生物技术有限公司开始研发世界上第一个溶瘤病毒产品——今又生（H101），并于 2005 年 11 月在中国通过了 III 期临床试验，与化疗联合用于治疗鼻咽癌，随后于 2006 年 8 月获得了 GMP 证书。本文将介绍今又生在中国的研发历程，以及 2006 年上市后中国市场的反应。
